Post Subject #325   Vasant Narasimhan becomes CEO 2/1/18—succeeding Joe Jimenez: #msg-134366063. DewDiligence 09/04/17 10:41:21 AM #325   Vasant Narasimhan becomes CEO 2/1/18—succeeding Joe Jimenez: #msg-134366063. DewDiligence 09/04/17 10:41:21 AM #324   https://seekingalpha.com/article/4103595-novartis-history-made-future-cancer-tre Inoviorulez 09/01/17 07:42:32 PM #323   Kymriah/CAR-T outcomes-based pricing: #msg-134254831. DewDiligence 08/30/17 11:22:03 AM #322   FDA approves NVS’ Kymriah (CTL019 CAR-T) for pediatric ALL: DewDiligence 08/30/17 11:02:14 AM #321   New drug from Novartis helps prevent heart attacks biotech_researcher 08/27/17 07:51:53 AM #320   https://seekingalpha.com/article/4089618-amgen-novartis-first-mover-advantage-mu Inoviorulez 07/23/17 02:28:42 AM #319   Sell short this crap along with other big pharma... malt66 07/18/17 08:27:34 PM #317   NVS 2Q17 CC slides: DewDiligence 07/18/17 01:36:07 PM #316   https://seekingalpha.com/article/4087475-novartis-wins-fda-panel-backing-new-car Inoviorulez 07/13/17 10:07:15 AM #315   NVS’ own PR on CTL019 ODAC panel: DewDiligence 07/13/17 09:44:32 AM #314   FDA approves Tafinlar+Mekinist for BRAF-V600E NSCLC: #msg-132422635. DewDiligence 06/22/17 06:41:33 PM #313   Ilaris reduces MACE in secondary-prevention setting: #msg-132398529. DewDiligence 06/22/17 09:12:42 AM #312   RTH258 non-inferior to Eylea with less-frequent injections: #msg-132328161. DewDiligence 06/20/17 09:15:40 AM #311   EU approves NVS’ Rituxan FoB, called Rixathon: DewDiligence 06/19/17 11:43:31 AM #310   NVS “Meet the Management” Investor Day slides: DewDiligence 05/31/17 08:41:54 AM #309   CHMP approves Zykadia in first-line ALK+ NSCLC: DewDiligence 05/19/17 10:08:45 AM #308   https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555778.htm?source= mikekrane 04/28/17 12:17:29 PM #307   NVS 1Q17 CC slides: DewDiligence 04/25/17 07:09:11 PM #306   NVS could take $15-25B loss on Alcon sale: DewDiligence 04/21/17 11:23:13 AM #305   NVS, AGN collaborate on phase-2b for NASH combo: #msg-130568056. DewDiligence 04/18/17 11:00:25 AM #304   NVS licenses dry-eye drug candidate from (private) Lubris, DewDiligence 04/07/17 11:24:09 AM #303   Serelaxin fails revamped phase-3 trial in acute HF: #msg-129752197. DewDiligence 03/22/17 09:44:43 AM #302   FDA approves NVS’ Kisqali (f/k/a LEE011) for first-line DewDiligence 03/13/17 05:57:43 PM #301   Novartis AG (ADR) (NYSE:NVS) Fined And Some Products trendmkr 03/03/17 12:56:01 PM #300   Novartis AG (NYSE:NVS) Greater Use Of Technology In trendmkr 02/14/17 12:13:58 PM #298   Some info about NVS’ RTH258 for AMD: #msg-128240149. DewDiligence 01/29/17 06:53:41 PM #297   NVS CC slides… DewDiligence 01/25/17 07:04:17 AM #296   NVS inks two deals… DewDiligence 12/20/16 09:43:21 AM #295   Down nearly 4% in one day on good Ecomike 10/25/16 07:40:53 PM #294   NVS 3Q16 CC slides: DewDiligence 10/25/16 10:25:03 AM #293   NVS’ LEE011 data impress in first-line HR+/HER2- breast DewDiligence 10/08/16 04:45:07 PM #292   NVS presents phase-3 data in SPMS: DewDiligence 09/18/16 03:56:47 PM #291   NVS reduces MNTA stake via 10b5-1 plan: #msg-124870976. DewDiligence 08/30/16 05:57:38 PM #290   What will NVS do about AMGN's Enbrel patent DewDiligence 08/30/16 05:56:51 PM #289   FDA approves NVS’ Enbrel FoB, but... #msg-124870707. DewDiligence 08/30/16 05:35:31 PM #288   NVS hits phase-3 primary endpoint in SPMS: DewDiligence 08/25/16 10:21:36 AM #287   Novartis AG Licenses LGT209 To Cyon Therapeutics, Teams venturecapp 08/24/16 12:22:56 PM #286   NVS’ recent-launch successes—Cosentyx yes, Entresto no: DewDiligence 07/19/16 11:24:57 AM #285   FDA rejects NVS' Enbrel FoB: #msg-123963130. DewDiligence 07/19/16 10:31:47 AM #284   NVS 2Q16 CC slides: DewDiligence 07/19/16 10:30:23 AM #283   will be 90 by next year Fibanotch 06/10/16 05:11:59 PM #282   Novartis, Eisai To Cooperate In Cancer Drugs Marketing venturecapp 06/08/16 10:50:38 AM #281   NVS to run 40+ Entresto trials to boost sales: DewDiligence 05/19/16 04:10:33 PM #280   $NVS recent news/filings stocktrademan 03/18/16 04:33:30 PM #279   Entresto is off to a slow start: #msg-121250538. DewDiligence 03/16/16 06:20:43 PM #278   Looks like Offices are being Raided over Bribery PENNYMACHINE 02/22/16 12:22:29 PM #277   The 20-F annual report has been filed: DewDiligence 01/27/16 08:34:50 AM #276   NVS 4Q15 CC slides: DewDiligence 01/27/16 07:08:54 AM #275   Alcon has become a serious drag on NVS: #msg-119762239. DewDiligence 01/11/16 07:42:12 PM #274   Entresto might increase risk of AMD and AD, DewDiligence 12/10/15 03:25:56 PM Post Subject

© 2017 InvestorsHub.Com, Inc.